Stocks Health care KLRA
NASDAQ · Health careKailera Therapeutics, Inc. (KLRA)
At September 30, 2026 it held $106.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Kailera Therapeutics, Inc.
- Net worth
- Kailera Therapeutics, Inc. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Kailera Therapeutics, Inc.'s next report is expected around January 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Kailera Therapeutics, Inc. does
Kailera Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KLRA.
Earnings: every quarter and the next report date
Latest SEC filings
What Kailera Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 12, 2026
- August 5, 2026Passive stake (5% or more) SCHEDULE 13G
- May 26, 2026
- May 26, 2026
- April 23, 2026Activist stake (5% or more) SCHEDULE 13D
Insider trades
What the people running Kailera Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 9, 2026 | Renaud Ronald C JRCEO & President, Director | Exercised options | 38,094 | $200K |
| April 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% owner | Exercised options | 9,477,719 | - |
| April 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% owner | Exercised options | 2,034,133 | - |
| April 20, 2026 | Rtw Investments, LP10% owner | Exercised optionsindirect | 10,276,820 | - |
| April 20, 2026 | Rtw Investments, LP10% owner | Boughtindirect | 500,000 | $8M |
| April 20, 2026 | Kaplan Andrew T.Director, 10% owner | Exercised optionsindirect | 17,857,143 | - |
| April 20, 2026 | Kaplan Andrew T.Director, 10% owner | Boughtindirect | 8,398,438 | $134.4M |
| April 20, 2026 | Bain Capital Life Sciences Investors, LLC10% owner | Exercised optionsindirect | 16,875,000 | - |
Who owns KLRA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BCPE Perseus Investor, LP13D, may seek influence | 20.27% | April 23, 2026 |
| BCLS Fund IV Investments, L.P.13D, may seek influence | 17.43% | April 23, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.13G, passive | 8.9% | August 5, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 8.3% | August 14, 2026 |
| CPP Investment Board Private Holdings (4) Inc.13G, passive with 1 related filers | 5.6% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 99 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bain Capital Investors LLC | 26,255,581 | new |
| Bain Capital Life Sciences Investors, LLC | 22,583,268 | new |
| Rtw Investments, LP | 10,776,820 | new |
| Canada Pension Plan Investment Board | 7,304,688 | new |
| Atlas Venture Life Science Advisors, LLC | 5,171,282 | new |
| Fmr LLC | 3,970,865 | new |
| BlackRock, Inc. | 3,928,604 | new |
| Citadel Advisors LLC | 3,240,787 | new |
| Adage Capital Partners GP, L.L.C. | 3,208,286 | new |
| Wellington Management Group Llp | 2,919,110 | new |
| Royalty Pharma Sub-Manager, LLC | 2,455,357 | new |
| Siren, L.L.C. | 2,214,286 | new |
| Vanguard Capital Management LLC | 1,693,958 | new |
| Vanguard Portfolio Management LLC | 1,652,507 | new |
| Geode Capital Management, LLC | 1,133,115 | new |
| Farallon Capital Management, L.L.C. | 1,100,000 | new |
| Frazier Life Sciences Management, L.P. | 1,100,000 | new |
| Trails Edge Capital Partners, LP | 984,786 | new |
| UBS Group AG | 972,683 | new |
| Jupiter Topco LLC | 970,857 | new |
Insiders
7 insiders reported holding 110,526,745 shares in total, about $1.57B at the last price.
| Holder | Shares |
|---|---|
| Bain Capital Investors LLC10% owner | 26,255,58126,255,581 held indirectly |
| Kaplan Andrew T.Director, 10% owner | 26,255,58126,255,581 held indirectly |
| Koppel AdamDirector, 10% owner | 22,583,26822,583,268 held indirectly |
| Bain Capital Life Sciences Investors, LLC10% owner | 22,583,26822,583,268 held indirectly |
| Rtw Investments, LP10% owner | 10,776,82010,776,820 held indirectly |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% owner | 2,034,133 |
| Renaud Ronald C JRCEO & President, Director | 38,094 |
Questions about KLRA
What does Kailera Therapeutics, Inc. do?
Kailera Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as KLRA. Its shares trade on NASDAQ under the ticker KLRA.
What is Kailera Therapeutics, Inc.'s net worth?
Kailera Therapeutics, Inc. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
When did Kailera Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Kailera Therapeutics, Inc.'s next earnings report?
Kailera Therapeutics, Inc.'s next report is expected around January 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KLRA with
Follow KLRA
Get an email when Kailera Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kailera Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.